In Shanghai on October 14, 2025, Mabwell (688062.SH), a comprehensive biopharmaceutical firm, reported that the clinical trial findings of its new B7-H3-targeting ADC (Research & Development code: 7MW3711) for numerous advanced solid tumors will be showcased in a poster presentation.